USPTO serial 97512123
SATIO
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- PRIZANT, JAMES
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SATIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Boston, MA, US
Boston, MA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joshua S. Jarvis, Esq.
Joshua S. Jarvis, Esq. FOLEY HOAG LLP155 SEAPORT BOULEVARDBOSTON, MA 02210United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Vaccines, namely, dermal patches featuring vaccines; pharmaceutical preparations for the prevention and treatment of infectious diseases and non-infectious diseases, namely, dermal patches featuring pharmaceutical preparations for the prevention and treatment of hepatic diseases, immune system diseases, renal diseases, metabolic diseases, endocrine diseases, thyroid diseases, diabetes, pancreatic diseases, cystic fibrosis, phenylketonuria, blood diseases, sickle cell disease, sickle cell anemia, galactosemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency; medical diagnostic reagents and assays for testing of body fluids, namely, dermal patches featuring medical diagnostics or assays for testing of body fluids; reagents for use in medical genetic testing, namely, dermal patches featuring reagents for use in medical genetic testing | ACTIVE | — |
| 010 | Medical diagnostic apparatus for testing DNA and RNA samples; medical diagnostic apparatus for testing for infectious diseases and non-infectious diseases, namely, hepatic diseases, immune system diseases, renal diseases, metabolic diseases, endocrine diseases, thyroid diseases, diabetes, pancreatic diseases, cystic fibrosis, phenylketonuria, blood diseases, sickle cell disease, sickle cell anemia, galactosemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency; genetic testing apparatus for medical purposes; dermal patches for delivery of pharmaceuticals and vaccines, sold empty; medical devices for obtaining body fluid samples; medical devices for testing body fluid samples; dermal patches for testing DNA and RNA samples; dermal patches for testing for infectious diseases and non-infectious diseases, namely, hepatic diseases, , immune system diseases, renal diseases, metabolic diseases, endocrine diseases, thyroid diseases, diabetes, pancreatic diseases, cystic fibrosis, phenylketonuria, blood diseases, sickle cell disease, sickle cell anemia, galactosemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency; dermal patches for testing for genetic testing; dermal patches for obtaining body fluid samples; dermal patches for testing body fluid samples | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 1, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 1, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 4, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 3, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Apr 3, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Apr 3, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 18, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 18, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 18, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 18, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 27, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 26, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 26, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 26, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 30, 2023 | NOAC | CORRECTED NOA E-MAILED | — |
| Nov 29, 2023 | ICNA | NOTICE OF ALLOWANCE CORRECTION ENTERED | — |
| Nov 9, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 31, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 24, 2023 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Sep 5, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 5, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 16, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 29, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 28, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 27, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 27, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 18, 2023 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 18, 2023 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 18, 2023 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 17, 2023 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 17, 2023 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 17, 2023 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 5, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 10, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 23, 2022 | NWAP | NEW APPLICATION ENTERED | — |